HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01199614
• Date of registration: 09/09/2010
• Prospective Registration: No
• Primary sponsor: John P. Bilezikian
• Public title: HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
• Scientific title: HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism
• Date of first enrolment: December 2009
• Target sample size: 75
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT01199614
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 3

Countries of recruitment

United States

Contacts

• Name: John P Bilezikian, MD
• Affiliation: Columbia University

Key inclusion & exclusion criteria

For Returning Participants or participants graduating from one of the parent studies:

Inclusion Criteria:

- Must have participated in and concluded the CL1-11-040, PAR-C10-007 or PAR-C10-008
Study at any site in the continental United States

- Must have participated in and concluded the Hypopara Study at Columbia University

Exclusion Criteria:

- failure to have completed either of the inclusionary studies

For New Participants (20 anticipated):

INCLUSION CRITERIA:

1. Signed and dated informed consent form (ICF) before any study-related procedures are
performed.

2. Adult males or females 18 to 85 years of age.

3. History of hypoparathyroidism for = 18 months, including evidence of hypocalcemia and
concomitant serum intact PTH concentrations below the lower limit of normal within 12
months prior to Baseline.

4. Requirement for calcitriol =0.25 mcg per day per day prior to Baseline.

5. Requirement for supplemental oral calcium = 1500 mg per day between supplemental and
dietary sources.

6. Serum thyroid function tests within normal laboratory limits at screening for all
subjects not receiving thyroid hormone replacement therapy. For patients on thyroid
hormone replacement therapy, the dose must have been stable for at least 3 months
prior to screening

7. serum creatinine < 1.5 mg/dL on a single measurement prior to use of study drug

8. Physically capable of performing daily subcutaneous (SQ) self-injections, in the
thigh, of study medication (or have designee perform injection).

9. Willingness and ability to comply with the protocol (prior to screening).

10. With regard to female patients: Women of childbearing potential must have a negative
pregnancy test at Screening and agree to use two medically acceptable methods of
contraception for the duration of the study with pregnancy testing at every scheduled
visit.

EXCLUSION CRITERIA:

Patients who have any of the following during the screening visit are not eligible for
enrollment in this study:

1. Known history of hypoparathyroidism resulting from an activating mutation in the CaSR
gene or impaired responsiveness to PTH (pseudohypoparathyroidism). If unknown, it
shall be assumed to be not-present.

2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis
other than hypoparathyroidism, such as active hyperthyroidism, Paget's disease,
insulin-dependent diabetes mellitus (IDDM) or poorly controlled Type II diabetes
mellitus (HbA1C > 8%), severe and chronic cardiac, liver or renal disease, Cushing's
syndrome, neuromuscular disease such as rheumatoid arthritis, myeloma, pancreatitis,
malnutrition, rickets, recent prolonged immobility, active malignancy, primary or
secondary hyperparathyroidism, a history of parathyroid carcinoma, hypopituitarism,
acromegaly, or multiple endocrine neoplasia types I and II.

3. To be eligible, patients with a history of thyroid cancer must be documented to be
disease-free for a period of at least 5 years (or 2 years with evidence of follow up
and a doctor's note of clearance).

4. Patients dependent on regular parenteral calcium infusions (e.g. calcium gluconate) to
maintain calcium homeostasis.

5. Patients that have undergone gastric resection or have active peptic ulcer disease
requiring medical therapy.

6. Use of prohibited medications such as, raloxifene hydrochloride, lithium,
methotrexate, or systemic corticosteroids within the last 6 months.

7. Treatment with PTH-like drugs, including PTH(1-84), PTH(1-34) or other N terminal
fragments or analogs of PTH or PTH-related protein within the last 6 months.

8. Other drugs known to influence calcium and bone metabolism, such as calcitonin, sodium
fluoride, or cinacalcet hydrochloride within the last 6 months.

9. Use of oral bisphosphonates within the previous 6 months or IV bisphosphonate
preparations within the previous 12 months prior to screening.

10. Seizure disorder/epilepsy and a history of a documented seizure within the previous 6
months.

11. In regard to participants between 18 and 21 years of age: Presence of open epiphyses
as determined by x-ray.

12. Radiotherapy to the skeleton within 5 years.

13. Serum 25-hydroxyvitamin D levels greater than 1.5-fold the laboratory upper limit of
normal. (i.e., > 150 ng/mL)

14. Any disease or condition in the opinion of the Investigator that has a high
probability of precluding the patient from completing the study or where the patient
cannot or will not appropriately comply with study requirements.

15. Participation in any other investigational trial in which receipt of investigational
drug or device occurred within 6 months prior to screening for this study.

16. Pregnant or lactating women.

17. History of diagnosed drug or alcohol dependence within the previous 3 years.

18. Clinical history of renal calculi within the past 6 months.

19. Any condition that negatively affects gastrointestinal absorption, including but not
limited to short bowel syndrome, bowel resection, tropical sprue, celiac disease,
ulcerative colitis, and Crohn's disease.

20. Chronic/severe cardiac disease including but not limited to cardiac insufficiency,
arrhythmias, bradycardia (resting heart rate < 60 beats/minute), or hypotension
(systolic and diastolic blood pressures < 100 and 60 mmHg, respectively).

21. History of cerebrovascular accident (CVA) in the past 5 years or earlier, if there is
residual impairment that would affect participation in the study.



Age minimum: 18 Years
Age maximum: 85 Years
Gender: All

Health Condition(s) or Problem(s) studied

Hypoparathyroidism

Intervention(s)

Drug: open-label PTH(1-84)

Primary Outcome(s)

Change in Dose of Calcium Supplementation [Time Frame: Baseline vs. Up to 12 Years]

Secondary Outcome(s)

Percent Change in BMD by DXA [Time Frame: Baseline vs. Up to 12 Years]

Secondary ID(s)

AAAE0544

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

NPS Pharma

Shire